株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

乾性角結膜炎 (ドライアイ) :パイプライン製品の分析

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 219724
出版日 ページ情報 英文 201 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
乾性角結膜炎 (ドライアイ) :パイプライン製品の分析 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017
出版日: 2017年09月30日 ページ情報: 英文 201 Pages
概要

ドライアイ症候群は、乾性角結膜炎 (KCS) や乾燥角膜炎としても知られている、涙液および目の表面の多因子疾患です。目の表面への潜在的な損傷によって、不快感、視覚障害、涙液層の不安定性をもたらします。目の疲れ、まぶしさ、充血、目やになどの症状が見られます。危険因子は、年齢のほか、レーザー眼科手術、薬剤投薬などが原因となる場合もあります。

当レポートでは、乾性角結膜炎 (ドライアイ) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

乾性角結膜炎 (ドライアイ) の概要

治療薬の開発

  • パイプライン製品の概要

乾性角結膜炎 (ドライアイ) :企業で開発中の治療薬

乾性角結膜炎 (ドライアイ) :パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

乾性角結膜炎 (ドライアイ) :企業で開発中の製品

乾性角結膜炎 (ドライアイ) の治療薬開発に従事している企業

  • AB2 Bio Ltd.
  • Akari Therapeutics, Plc
  • Allergan Plc
  • Circadian Technologies Limited
  • Delenex Therapeutics AG
  • Digna Biotech, S.L.
  • Dompe Farmaceutici S.p.A.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Huons Co., Ltd.
  • InSite Vision Incorporated
  • Kala Pharmaceuticals, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lipicard Technologies Limited
  • Merck & Co., Inc.
  • Mimetogen Pharmaceuticals Inc.
  • Mitotech S.A.
  • Nanomerics Ltd
  • Neuroptis Biotech
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • OncoNOx ApS
  • 大塚ホールディングス
  • Parion Sciences, Inc.
  • PharmaReaserch Products Co., Ltd.
  • RegeneRx Biopharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Samjin Pharmaceutical Co., Ltd.
  • 参天製薬
  • 生化学工業
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • TearSolutions, LLC.
  • Xigen SA

乾性角結膜炎 (ドライアイ) :治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

乾性角結膜炎 (ドライアイ) :最近のパイプライン動向

乾性角結膜炎 (ドライアイ) :休止中のプロジェクト

乾性角結膜炎 (ドライアイ) :開発が中止された製品

乾性角結膜炎 (ドライアイ) :製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9753IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keratoconjunctivitis sicca (Dry Eye) - Overview
    • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
    • Alcon Laboratories Inc
    • Aldeyra Therapeutics Inc
    • Allergan Plc
    • Ascendia Pharmaceuticals LLC
    • BioLineRx Ltd
    • Cambium Medical Technologies LLC
    • Chong Kun Dang Pharmaceutical Corp
    • Clementia Pharmaceuticals Inc
    • Dompe Farmaceutici SpA
    • Elasmogen Ltd
    • HanAll Biopharma Co Ltd
    • Herantis Pharma Plc
    • Huons Global Co Ltd
    • InSite Vision Inc
    • Kala Pharmaceuticals Inc
    • KPI Therapeutics Inc
    • Kukje Pharmaceutical Industry Co Ltd
    • Laboratoires Thea SA
    • Lipicard Technologies Ltd
    • Merck & Co Inc
    • Mitotech SA
    • Nanomerics Ltd
    • Nemus Bioscience Inc
    • Novaliq GmbH
    • Ocular Therapeutix Inc
    • Oculis ehf
    • OncoNOx ApS
    • Otsuka Holdings Co Ltd
    • Quorum Innovations LLC
    • Redwood Pharma AB
    • RegeneRx Biopharmaceuticals Inc
    • Samjin Pharm Co Ltd
    • Santen Pharmaceutical Co Ltd
    • Seikagaku Corp
    • Shire Plc
    • Sun Pharma Advanced Research Company Ltd
    • Sylentis SAU
    • TearSolutions LLC
    • TopiVert Ltd
    • Vanda Pharmaceuticals Inc
    • Xigen SA
  • Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles
    • ADP-355 - Drug Profile
    • ADP-399 - Drug Profile
    • ADX-102 - Drug Profile
    • ADX-103 - Drug Profile
    • AGN-223575 - Drug Profile
    • AGN-232411 - Drug Profile
    • AL-41A1 - Drug Profile
    • AVA-3486 - Drug Profile
    • AVX-012 - Drug Profile
    • AX-1606 - Drug Profile
    • BL-1230 - Drug Profile
    • BRM-421 - Drug Profile
    • cenegermin - Drug Profile
    • cinhyaluronate sodium - Drug Profile
    • Cis-Urocanic Acid - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine - Drug Profile
    • cyclosporine SR - Drug Profile
    • dexamethasone acetate SR - Drug Profile
    • diclofenac sodium - Drug Profile
    • diquafosol tetrasodium - Drug Profile
    • Drug for Dry Eye - Drug Profile
    • ECF-843 - Drug Profile
    • Elate Ocular - Drug Profile
    • ELN-22 - Drug Profile
    • HL-036 - Drug Profile
    • HU-007 - Drug Profile
    • hyaluronate sodium - Drug Profile
    • ISV-101 - Drug Profile
    • K-089 - Drug Profile
    • KeraKlear - Drug Profile
    • KJ-14003 - Drug Profile
    • KJ-16001 - Drug Profile
    • KPI-190 - Drug Profile
    • Lacripep - Drug Profile
    • Leukothera - Drug Profile
    • lifitegrast - Drug Profile
    • LME-636 - Drug Profile
    • loteprednol etabonate - Drug Profile
    • LT-4003 - Drug Profile
    • NB-2222 - Drug Profile
    • Nov-03 - Drug Profile
    • Nov-07 - Drug Profile
    • OC-301 - Drug Profile
    • OCX-071 - Drug Profile
    • OTX-101 - Drug Profile
    • OX-1001 - Drug Profile
    • palovarotene - Drug Profile
    • plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    • PPL-003 - Drug Profile
    • Protearin - Drug Profile
    • Qi-401 - Drug Profile
    • rebamipide - Drug Profile
    • RGN-259 - Drug Profile
    • RP-101 - Drug Profile
    • SA-001 - Drug Profile
    • SHP-659 - Drug Profile
    • SJP-002 - Drug Profile
    • solithromycin - Drug Profile
    • ST-266 - Drug Profile
    • Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders - Drug Profile
    • SYL-1001 - Drug Profile
    • tadekinig alfa - Drug Profile
    • TOP-1630 - Drug Profile
    • XG-104 - Drug Profile
    • zucapsaicin - Drug Profile
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
  • Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Alcon Laboratories Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Elasmogen Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sylentis SAU, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top